Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

(Staccato loxapine) is being developed for the acute treatment of migraine headaches. AZ-104 is a lower dose version of AZ-004. In March 2008, the Company announced initial results of an in-clinic, multi-center, randomized, double-blind, single administration, placebo-controlled Phase 2a proof-of-concept clinical trial in 168 migraine patients with or without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were evaluated against placebo in the clinical trial. Using the IHS (International Headache Society) 4-point rating scale, the primary efficacy endpoint was pain-relief response at 2 hours post-administration. AZ-104 met the primary efficacy endpoint of the clinical trial for two dose levels of the drug compared to placebo. Statistically significant improvements in pain response were observed in 76.7% of patients at the 5 mg dose (p = 0.02), 79.1% of patients at the 2.5 mg dose (p = 0.01) and 67.4% of patients at the 1.25 mg dose (p = 0.18), compared to 51.3% of patients receiving placebo. Using survival analysis for pain relief response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic. AZ-004 is being developed through Symphony Allegro.

-- AZ-002 (Staccato alprazolam) is being developed for the acute treatment of panic attacks associated with panic disorder. Alexza is conducting a Phase 2a proof-of-concept clinical trial in panic disorder patients. The primary aim of the in-clinic trial is to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack. Alexza has completed the open-label, lead-in segment of the study, identifying the 1 mg AZ-002 dose as an acceptable dose in terms of safety and efficacy. Alexza expects the enrollment of this clinical trial to be completed in Q2 2008. AZ- 002 is also being developed through Symphony Allegro.

-- AZ-003 (Staccato fentanyl) is being developed
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:5/22/2015)... 2015 Family, friends, students, colleagues, mentors ... oncologist, Dr. LaSalle D. Leffall, on Monday, May 18, ... after Grand Rounds in the hospital’s Tower Auditorium. Leffall’s ... the auditorium, trying to keep the secret. “I’d like ... sees me, he’ll know something is up,” she said. ...
(Date:5/22/2015)... Knoxville, TN (PRWEB) May 22, 2015 Power ... Andrew Drobeck for the 2015 race season. Drobeck is in ... also serves as a firefighter with the Missoula Fire Department ... and became a Pro in 2014. During his career, he ... as a Pro, Drobeck recorded top 10 finishes in all ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all forms of ... in include decks, additions, kitchen remodeling, interior renovations, exterior ... , The redesigned logo is a fresh modern ... includes two geometrical lines that represent the engineering aspect ... used with many things associated with the company. The ...
(Date:5/22/2015)... 22, 2015 DMG Productions announces the ... to broadcast on Friday, May 29, 2015 at 7:30 ... , In this episode Innovations will explore Interstate Restoration, ... business quickly through disaster recovery and restoration. , Additionally, ... works collaboratively to develop and deliver training and education ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS ... dentists to immediately deliver fully integrated dental implant services to ... the medical surgeon. , The Center, whose name is ... dentists from placing dental implants. These 6 roadblocks can ... the surgical placement of dental implants into his or her ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... , Researchers have undertaken a large-scale investigation ... protein (APP), a protein centrally associated with Alzheimer,s ... is the extracellular accumulation of amyloid plaques in ... cleavage of APP, which generates short, sticky fragments ...
... have identified a number of new genes that can ... that hopefully might be used to treat the disease ... These unique findings are being published in three ... Genetics. , SLE (systemic lupus erythematosus) is a so-called ...
... of Neurosciences at Mount Sinai School of Medicine have ... novel targeted gene therapy. In an effort to find ... Mount Sinai developed a gene therapy technique that simulates ... study Sensory neuron targeting by self-complementary AAV8 via lumbar ...
... 2007 An international research team, led by a ... (CHUM), has identified new therapeutic targets for the treatment ... Nature Immunology, the team provides fresh answers concerning the ... MS, a chronic autoimmune disease of the nervous system ...
... study says , , TUESDAY, Jan. 22 (HealthDay News) -- ,A ... liver cancer also increases the risk of developing high blood ... carefully monitored and treated, said the authors of a study ... Oncology . , Nexavar is an anti-angiogenesis drug, meaning it ...
... A new study reveals significant racial and ethnic differences ... sarcomas, a rare but dangerous cancer that begins in ... the body. The findings are published in the March ... the American Cancer Society. , While racial and ethnic ...
Cached Medicine News:Health News:Story ideas from Molecular and Cellular Proteomics 2Health News:Researchers find relief for chronic pain 2Health News:New therapeutic target for treatment of multiple sclerosis 2Health News:Liver Cancer Drug Raises Blood Pressure 2Health News:Disparities among patients with extremity soft-tissue sarcomas 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: